Protagonist Therapeutics earnings release, August 5, 2026

Protagonist Therapeutics, Inc (PTGX) · Form 8-K, Item 2.02 · Filed · SEC filing

Protagonist

Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™

First Full Quarter of Commercial Sales with Strong Early Adoption

Rusfertide

NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026

Comprehensive

Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psoriasis, Planned to Initiate Early Q1 2027

Phase

1 Study Initiated with PN-477sc, a Triple GLP1/GIP/GCG Agonist Peptide for Obesity

Cash,

Cash Equivalents and Marketable Securities of $849.5 Million as of June 30, 2026

NEWARK, Calif., August 5, 2026 – Protagonist

Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.

"The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner and accelerating momentum across our internal R&D pipeline. ICOTYDE is quickly becoming a paradigm-shifting oral therapy for patients with moderate-to-severe plaque psoriasis, and rusfertide is approaching an FDA decision that could establish it as a first-in-class erythrocytosis targeted medicine for patients with polycythemia vera,” said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist Therapeutics.

“Equally exciting is the decision to advance our wholly-owned oral IL-17 antagonist PN-881 into a comprehensive Phase 2b psoriasis program, based on the strongly supportive pharmacokinetic results from the Phase 1 study. Behind PN-881, we have a maturing set of diverse assets moving toward clinical studies in obesity, hematology and immunology. These are the results of years of disciplined investment in differentiated science and mark the beginning, not the culmination, of a new phase of value creation as we continue to advance our peptide platform and clinical pipeline.”

Second

Quarter 2026 Recent Developments and Upcoming Milestones

Rusfertide:

Subcutaneous

Injectable Hepcidin Mimetic for Polycythemia Vera (PV)

ICOTYDE™

(Icotrokinra): Oral IL-23 Receptor Antagonist

Wholly-Owned Clinical and Discovery

Programs¹

Additional information provided on slides 24 and 25 in the corporate deck posted to the corporate website as well as in the 8-K filed with the SEC on August 5,

2026

Second Quarter 2026 Financial Results

License and Collaboration Revenue

:

License and collaboration revenue of $213.5 million for second quarter of 2026 consisted primarily of (i) $192.4 million related to proportional recognition of the initial $200.0 million opt-out payment received from Takeda and (ii) $21.1 million for ongoing development services, including post opt-out wind down services, and rusfertide clinical supplies provided by us under the Takeda Collaboration Agreement and other revenues.

License and collaboration revenue of $269.8 million for six months ended June 30, 2026 consisted primarily of (i) $192.4 million related to proportional recognition of the initial

$200.0 million opt-out payment received from Takeda, (ii) $27.4 million for ongoing development services, including post opt-out wind down services, and rusfertide clinical supplies provided by us under the Takeda Collaboration Agreement and other revenues, and (iii) a $50.0 million milestone earned from JNJ in Q1 2026 upon FDA approval of ICOTYDE.

License and collaboration revenue of

$5.5 million for second quarter of 2025 consisted of (i) $5.0 million related to the initial transaction price of the Takeda collaboration agreement for development services provided by us, and (ii) $0.5 million related to the proportional recognition of the $25 million milestone earned in Q1 2025 but receivable following completion of the VERIFY clinical study report. License and collaboration revenue of $33.9 million for the six months ended June 30, 2025 consisted of: (i) $23.4 million related to proportional recognition of the $25 million milestone earned in Q1 2025 but payable following completion of the VERIFY clinical study report, and (ii) $10.5 million allocated to development services provided by us under the agreement during the period.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™

(icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the

Interleukin-23 receptor. ICOTYDE, launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and

Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization.

Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda

Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its...line drug candidates and its clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Cautionary Note on

Financial statements

Income Statement

Three Months Ended — Second Quarter 2026 Financial Results (in thousands, except per share amounts)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
License and collaboration revenue213,4755,546269,84333,867
Research and development expense42,06137,03688,80072,929
General and administrative expense12,64810,55125,92522,289
Income tax expense2,265172763172
Net income (loss)162,849-34,771166,632-46,426
Basic earnings (loss) per share2.47-0.552.54-0.73
Diluted earnings (loss) per share2.29-0.552.35-0.73

Income Statement

Three Months Ended — (Amounts in thousands except share and per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
License and collaboration revenue213,4755,546269,84333,867
Operating expense:Research and development (1)42,06137,03688,80072,929
Operating expense:General and administrative (1)12,64810,55125,92522,289
Operating expense:Total operating expense54,70947,587114,72595,218
Operating expense:Income (loss) from operations158,766-42,041155,118-61,351
Operating expense:Interest income6,4297,40612,30514,979
Operating expense:Other (expense) income, net-8136-28118
Operating expense:Income (loss) before income tax expense165,114-34,599167,395-46,254
Operating expense:Income tax expense2,265172763172
Operating expense:Net income (loss)162,849-34,771166,632-46,426
Operating expense:Net income (loss) per share, basic2.47-0.552.54-0.73
Operating expense:Net income (loss) per share, diluted2.29-0.552.35-0.73
Operating expense:Weighted-average shares used to compute net income (loss) per share, basic65,935,76963,510,53765,514,15063,238,682
Operating expense:Weighted-average shares used to compute net income (loss) per share, diluted71,007,01163,510,53770,818,71863,238,682

Balance Sheet

December 31, — (In thousands) (in thousands)

June 30, – 2026December 31, – 2025
Cash, cash equivalents and marketable securities849,451646,002
Working capital769,967532,133
Total assets885,544668,188
Deferred revenue9,6599,550
Accumulated deficit-304,039-470,671
Total stockholders' equity841,543614,707
Full release

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform

Act of 1995. Forward-looking statements include statements regarding potential revenue from the Company's collaborations with Johnson

& Johnson and Takeda, timing of regulatory actions and clinical trial completion, and advancement of the Company's discovery and clinical pipeline. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe,"

"may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone and royalty payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk

Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange

Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release.

We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.

Investor Relations Contact

Corey Davis, Ph.D.

LifeSci Advisors cdavis@lifesciadvisors.com

+1 212 915 2577

Media Relations Contact

Virginia Amann

ENTENTE Network of Companies virginiaamann@ententeinc.com

+1 833 500 0061 ext 1

PROTAGONIST THERAPEUTICS,

INC.

Consolidated

Statements of Operations

(Amounts in thousands except share and per share data)

(1) Amount includes non-cash stock-based compensation expense.

Stock-based

Compensation

(In thousands)

PROTAGONIST THERAPEUTICS,

INC.

Selected Consolidated

Balance Sheet Data

(In thousands)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.